GDTC.US CytoMed Therapeutics Limited Ordinary Shares

Healthcare Biotechnology USA Stocks
0.8293 USD
Close of Nov 13, 2026
0.6800 2.29
Market cap
USD 9.90M
P/E
-
P/B
2.60x
ROE
-106.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is GDTC.US undervalued?

Graham number

The Graham number of CytoMed Therapeutics Limited Ordinary Shares cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

CytoMed Therapeutics Limited Ordinary Shares fundamental analysis

No fundamental analysis for CytoMed Therapeutics Limited Ordinary Shares yet.

CytoMed Therapeutics Limited Ordinary Shares stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About CytoMed Therapeutics Limited Ordinary Shares

CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. It is also deve…

Full company profile